全踝置换、关节镜踝融合与开放踝融合治疗无畸形终末期踝关节炎的结局比较
基于COFAS前瞻性踝重建数据库的回顾性研究,纳入238例无畸形COFAS 1型终末期踝关节炎患者(TAR 88例、AAA 50例、OAA 100例),平均随访43.3个月。TAR和AAA的AOS总分与残疾评分改善显著大于OAA,但未达最小临床重要差异;TAR再手术率更高,三组翻修率相似。
要点
- TAR和AAA的AOS总分改善显著大于OAA(34.4、38.3 vs 25.8),但未达MCID。
- TAR组再手术率显著高于AAA和OAA组(p<0.0001),翻修率三组相似。
- AAA与OAA在无畸形COFAS 1型终末期踝关节炎中临床结局与TAR相当。
核心结论
- 在无畸形COFAS 1型终末期踝关节炎患者中,AAA和OAA的临床结局与TAR相当。
- TAR组件翻修率与AAA或OAA翻修率相似,但TAR患者接受了更多额外手术。
- 总体上,AAA与使用HINTEGRA假体的TAR在短期结局上无显著差异;应告知患者TAR再手术率更高。
研究设计与样本
- 回顾性识别2002至2012年接受TAR、AAA或OAA且随访至少2年的≥18岁患者,数据来自加拿大骨科足踝学会(COFAS)前瞻性踝重建数据库。
- 分析纳入229例患者的238踝(TAR 88、AAA 50、OAA 100),平均随访43.3±18.5个月。
- 证据等级为治疗性III级。
主要发现
- TAR组女性比例更高(55%;p=0.0318)且平均年龄更高(p=0.0005)。
- 术前AOS疼痛、残疾和总分三组相似;SF-36躯体与心理成分评分术前和术后组间均相似。
- AOS总分改善TAR 34.4±22.6、AAA 38.3±23.6,均显著大于OAA 25.8±25.5(p=0.005)。
- AOS残疾评分改善TAR 36.7±24.3、AAA 40.5±26.4,均显著大于OAA 26.0±26.2(p=0.0013)。
- 更大的改善未达最小临床重要差异;TAR组再手术多于AAA和OAA组(p<0.0001);三组翻修率相似(p=0.262)。
关键数值与推荐
- 纳入标准为有症状的COFAS 1型终末期踝关节炎,无关节内或关节外畸形,无周围关节关节炎。
- TAR翻修定义为移除1个或2个金属踝假体组件;AAA和OAA翻修定义为因位置不良、畸形愈合或不愈合而再手术。
- 临床结局采用踝骨关节炎量表(AOS)和SF-36评估。
临床怎么用
- 对于无畸形COFAS 1型终末期踝关节炎,AAA和OAA可取得与TAR相当的临床结局。
- 应向患者说明TAR再手术率高于AAA和OAA。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: End-stage ankle arthritis is a disabling condition that has a similar effect on morbidity, pain, and loss of function to hip arthritis. We compared clinical outcomes of total ankle replacement (TAR) involving the HINTEGRA prosthesis (Integra LifeSciences), arthroscopic ankle arthrodesis (AAA), and open ankle arthrodesis (OAA) in patients with isolated, non-deformed end-stage ankle arthritis. METHODS: Patients ≥18 years old who underwent TAR, AAA, or OAA from 2002 to 2012 with a minimum follow-up of 2 years were retrospectively identified from the Canadian Orthopaedic Foot and Ankle Society (COFAS) Prospective Ankle Reconstruction Database. All patients had symptomatic COFAS Type-1 end-stage ankle arthritis without intra-articular or extra-articular deformity or surrounding joint arthritis. Clinical outcomes included the Ankle Osteoarthritis Scale (AOS) and Short Form-36 (SF-36). Revision was defined as removal of 1 or both metal ankle prosthesis components for TAR and as reoperation for malposition, malunion, or nonunion for AAA and OAA. RESULTS: Analysis included 238 ankles (88 TAR, 50 AAA, and 100 OAA) in 229 patients with a mean follow-up of 43.3 ± 18.5 months. The TAR group had more female patients (55%; p = 0.0318) and a higher mean age (p = 0.0005). Preoperative AOS pain, disability, and total scores were similar for all groups. SF-36 physical and mental component summary scores were similar across groups, both preoperatively and postoperatively. Improvement in AOS total score was significantly larger for TAR (34.4 ± 22.6) and AAA (38.3 ± 23.6) compared with OAA (25.8 ± 25.5; p = 0.005). Improvement in AOS disability score was also significantly larger for TAR (36.7 ± 24.3) and AAA (40.5 ± 26.4) compared with OAA (26.0 ± 26.2; p = 0.0013). However, the greater improvements did not meet the minimal clinically important difference. The TAR group underwent more reoperations than AAA and OAA groups (p < 0.0001). Revision rates were similar for all 3 groups (p = 0.262). CONCLUSIONS: AAA and OAA resulted in comparable clinical outcomes to TAR in patients with non-deformed, COFAS Type-1 end-stage ankle arthritis. The rate of component revision in patients who underwent TAR was similar to the rate of revision for patients who underwent AAA or OAA; however, TAR patients underwent a greater number of additional procedures. Overall, AAA and TAR involving the HINTEGRA prosthesis were not significantly different surgical options in terms of short-term outcomes; patients should be counseled regarding higher reoperation rates for TAR. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Veljkovic AN, Daniels TR, Glazebrook MA, et al. Outcomes of Total Ankle Replacement, Arthroscopic Ankle Arthrodesis, and Open Ankle Arthrodesis for Isolated Non-Deformed End-Stage Ankle Arthritis. J Bone Joint Surg Am. 2019. PMID: 31483394. doi:10.2106/JBJS.18.01012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。